## Abstract ## Objective To confirm the reliability and applicability of the Polymyalgia Rheumatica Disease Activity Score (PMR‐AS), and to establish a threshold for remission. ## Methods First, 78 patients with PMR (50 women/28 men, mean age 65.97 years) were enrolled in a cross‐sectional evalu
Usefulness of the disease activity scores for polymyalgia rheumatica for predicting glucocorticoid dose changes: A study of 243 scenarios
✍ Scribed by Binard, Aymeric ;De Bandt, Michel ;Berthelot, Jean-Marie ;Saraux, Alain ;,
- Publisher
- John Wiley and Sons
- Year
- 2007
- Tongue
- English
- Weight
- 85 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Objective
To evaluate associations linking glucocorticoid dose changes in patients with polymyalgia rheumatica (PMR) to the PMR activity score (PMR‐AS) and its components.
Methods
Nine clinical vignettes of PMR were written by a panel of experts and submitted to 35 rheumatologists, who were asked to assess disease activity using a visual analog scale (VASph) and to determine whether there was a relapse of PMR requiring an increase in the glucocorticoid dose. In 7 vignettes, >80% of the rheumatologists agreed on the diagnosis of relapse justifying the glucocorticoid dose decision. A total of 243 vignette‐physician combinations were obtained. Using these vignettes, we evaluated statistical associations linking a decision to increase the glucocorticoid dose to the value of PMR‐AS, of its components (VASph, visual analog scale for pain [VASp], C‐reactive protein level [CRP], morning stiffness [MST], and elevation of upper limbs [EUL]), or to the difference in these variables between the last 2 visits (dPMR‐AS, dVASph, dVASp, dCRP, dMST, and dEUL).
Results
The strongest associations with a decision to increase the glucocorticoid dose occurred with dPMR‐AS >4.2, dMST >10 minutes, dVASph >1.55, and dCRP >4 mg/dl (99.3% sensitivity, 100% specificity for all 4 variables); MST ≥10 minutes (100% sensitivity, 99.3% specificity); PMR‐AS ≥7 (98.1% sensitivity, 94.3% specificity); VASph ≥2.25 (94.2% sensitivity, 83.6% specificity); and CRP level ≥14.5 mg/liter (66.3% sensitivity, 99.3% specificity).
Conclusion
Despite inter‐individual variations in VASph, PMR‐AS was a good indicator of disease activity. However, MST, dMST, dVASph, dPMR‐AS, and dCRP performed better than PMR‐AS. These variables may be useful in tailoring the glucocorticoid dose to the individual needs of each patient.
📜 SIMILAR VOLUMES
## Abstract ## Objective Venous thrombosis is a relatively frequent and serious complication in systemic lupus erythematosus (SLE) that has been associated with the presence of antiphospholipid antibodies (aPL). However, venous thrombotic events can also be seen in patients without aPL, and only a